ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1271

Plasma Concentration of S100A8/A9 Proteins Is an Independent Biomarker for Radiological Progression in in Early Rheumatoid Arthritis

Maxime Chevreau1, Marie Helène Paclet2, Jean-Louis Quesada3, Marine Clay4, Philippe Dieudé5,6, Olivier Vittecoq7, Philippe Gaudin8 and Athan Baillet9, 1Rheumatology, CHU Sud Hospital, Grenoble, France, 2IPB _ Grenoble teaching hospital, Grenoble, France, 3Grenoble University Hospital, France, Grenoble, France, Grenoble, France, 4Rheumatology Grenoble, Grenoble, France, 5Rheumatology, Bichat hospital APHP, Paris, France, 6Rheumatology, Hôpital Bichat, Paris, France, 7Rheumatology, Rouen University Hospital &INSERM U905, Rouen, France, 8Grenoble University Hospital, France, Grenoble, France, 9Rheumatology, Grenoble University Hospital, France, Echirolles, France

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: biomarkers and radiography, Early Rheumatoid Arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2016

Title: Imaging of Rheumatic Diseases - Poster II: XR/CT/PET/MRI

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Increasing body of evidence suggest that alarmins such as S100A8/A9 proteins play a critical role in Rheumatoid Arthritis pathogenesis (RA). We aimed to analyze the association between baseline S100A8/A9 protein plasma levels and radiological progression during the first 36 months of early RA.

Methods: Patients fulfilling the ACR/EULAR criteria in the early arthritis cohort ESPOIR were included in this study. S100A8/A9 (also known as calprotectin) levels were assessed in 813 patients of the early arthritis cohort ESPOIR at baseline. Total Sharp-van der Heijde score was assessed at baseline, year 1, 2 and 3. Univariate Cox regressions were used to evaluate the role of the risks factors to detect total Sharp-van der Heijde score progression ≥ 5 points /year. A multivariate risk model, comprising gender, age, baseline CRP,  baseline ACPA, baseline smoking status, baseline DAS28, baseline S100A8/A9 level and treatment with biologic or synthetic DMARD , was constructed using a backward stepwise Cox model. A patient was considered under DMARD treatment when receiving methotrexate≥7.5mg/sem, sulfasalazine, leflunomide or any biological treatment at least 6 months before radiological assessment.

Results: A total of 614 patients were included and analyzed out of 813 patients of the cohort. Significant differences were found between patients with or without radiological progression, in the univariate Cox model : progressors were more likely to be ACPA positive, to be treated biologic or synthetic DMARD and to display high level of baseline CRP and S100A8/A9 proteins (table). In the multivariate analysis, S100A8/A9 level was the only predictor of the structural evolution over 3 years, independently of usual marker of inflammation (Hazard ratio 1.06, 95%CI [1.00-1.11], p=0,045).           .

Conclusion: These results confirm that S100A8/A9 predicts radiological progression, in a large cohort of early rheumatoid arthritis. The correlation between this new biomarker and radiological progression was moderate but independent from other risk factors.  

 


Disclosure: M. Chevreau, None; M. H. Paclet, None; J. L. Quesada, None; M. Clay, None; P. Dieudé, None; O. Vittecoq, None; P. Gaudin, None; A. Baillet, None.

To cite this abstract in AMA style:

Chevreau M, Paclet MH, Quesada JL, Clay M, Dieudé P, Vittecoq O, Gaudin P, Baillet A. Plasma Concentration of S100A8/A9 Proteins Is an Independent Biomarker for Radiological Progression in in Early Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/plasma-concentration-of-s100a8a9-proteins-is-an-independent-biomarker-for-radiological-progression-in-in-early-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/plasma-concentration-of-s100a8a9-proteins-is-an-independent-biomarker-for-radiological-progression-in-in-early-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology